A Multicenter, Observational Registry of Pediatric Female Patients with Central Precocious Puberty Receiving Supprelin LA (Histrelin ACtate), A Hydrogel Subcutaneous Implant (IRB# 44479)

Status: Active



  • Principal Investigator- Peter A. Lee, MD



In girls, central precocious puberty (CPP) is defined as the onset of secondary sexual characteristics, increase in growth rate, and advancement of skeletal age beyond the chronological age before age 8 years.  If untreated, CPP results in the continuing advancement of epiphyseal maturation, which leads to decreased duration of linear growth and results in short final adult height. This latter consequence of early puberty can occur even when pubertal onset is "early" and not strictly before the age limits defined above.

SUPPRELIN LA is used to treat children with central precocious puberty. There are consequent concerns from healthcare professionals that the constant GnRH suppression in female children treated with SUPPRELIN LA could lead to delayed recovery of the reproductive axis and slow the progression toward the return to puberty once treatment has stopped . Long-term data, therefore, are needed to document the development of regular menstrual function in females with CPP who are treated with SUPPRELIN LA.           




Eligible patients will be female patients who are currently treated with, or have completed a course of treatment with, SUPPRELIN LA who were diagnosed by 8 years of age with Central Precocious Puberty or CPP and started on treatment with a GnRH agonist by 8.5 years of age.



Additional Study Details:

We will recruit participants from the Penn State Milton S. Hershey Medical Center via physician or nurse referral 



Penn State Milton S. Hershey Medical Center



Pediatric Clinical Research Office




  • Endocrinology